Menopause and MHT in 2024: addressing the key controversies – an International Menopause Society White Paper
The International Menopause Society (IMS) White Paper addresses the key controversies around menopause hormone therapy (MHT).
About IMS
The International Menopause Society (IMS) brings together the world’s leading experts to collaborate and share knowledge about all aspects of aging in women. The IMS advocates evidence-based treatment options that optimise mid-life women’s health and promote best practice in women’s health care.
IMS White Paper
The aim of the IMS White Paper is to provide a well-balanced educational narrative of the menopause and menopause hormone therapy (MHT) from IMS experts. The paper provides welcome advice and clarity from the misinformation that exists around menopause.
Hormone Health Founder and Director, Professor Nick Panay, the lead author of the IMS White Paper, said;
“Healthcare providers worldwide have a duty to provide a supportive, informative environment where women can freely discuss menopause as it affects them individually, express their concerns and priorities and receive personalized care to optimize their health and well-being in the second half of their lives.”
Prof Nick Panay
Hormone Health Founder and Director
At Hormone Health our experienced team, who have all trained with Prof Panay, provide evidence-based care in accordance with the principles in the IMS White Paper.
Key Points Summary
An important section of the paper is ‘The 5Ws of prescribing MHT’:
- WHO is MHT for;
- WHAT types and doses of MHT;
- WHEN should MHT be started and stopped;
- WHY is MHT important;
- WHERE can MHT be accessed?
The summary provides ‘easy access’ advice regarding several recent controversial MHT prescribing issues in the healthcare and media spotlights. Healthcare professionals and the public can access a key points summary of this information.